Quantum BioPharma's Lucid-MS Advances to Phase 2 MS Trial After FDA Clearance
September 10, 2026 — Quantum BioPharma's Lucid-MS advances to phase 2 MS trial after FDA IND clearance. Novel PAD2 inhibitor targets demyelination directly. Read more.
NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
September 10, 2026 — Quantum BioPharma's Lucid-MS advances to phase 2 MS trial after FDA IND clearance. Novel PAD2 inhibitor targets demyelination directly. Read more.
September 10, 2026 — GeoVax Labs appeals Nasdaq delisting, reaffirms focus on GEO-MVA vaccine and Gedeptin® cancer therapy. Hearing set for October 13, 2026.
September 10, 2026 — American Heart Association's PREVENT equations integrated into Epic EHR, enabling nationwide cardiovascular risk assessment and personalized prevention in routine care.
September 10, 2026 — BioCorRx appoints Richard J. Baum, former Acting Director of White House ONDCP, to Strategic Advisory Board to advance addiction treatment and policy strategies.
September 10, 2026 — Former Blue Ridge student returns as field staff, sharing how the wilderness therapy program transformed his life and family relationships, offering hope to others.
September 10, 2026 — Get MRI Now expands its rapid MRI referral service to nine new states, offering physician-authorized referrals in seconds for a flat $49.95 fee. Available in FL, TX, NV, CA, AZ, NM, IL, CO, NY, NJ.
September 10, 2026 — Fisher House SoCal releases a donor guide to help you choose the best military charity. Learn to evaluate transparency, impact, and support for veterans' families.
September 10, 2026 — Dr. Wael Sakr Scholarship for Medical Students offers $1,000 to pre-med undergrads. Apply by April 15, 2027. Essay required. Winner announced May 15, 2027.
September 10, 2026 — Dr. Thanapoom Boonipat Scholarship for Future Doctors offers $1,000 to undergraduates pursuing medical careers. Apply by April 15, 2027, with an essay on the future of medicine.
September 9, 2026 — Learn how to get affordable dental implants in Dallas without sacrificing quality. Compare providers, understand costs, and explore financing options for your tooth replacement.
September 9, 2026 — Visory Health named to Fast Company's 2026 Best Workplaces for Innovators. Discover how their innovative culture helps millions save on prescriptions.
September 9, 2026 — Tevard Biosciences publishes preclinical research in Science Advances on engineered suppressor tRNA therapy for Duchenne muscular dystrophy, showing restored dystrophin and improved muscle function.
September 9, 2026 — New stroke rehab guidelines from the American Stroke Association emphasize early, personalized care to improve recovery and quality of life for the 800,000 annual U.S. stroke survivors.
September 9, 2026 — Earth Science Tech (ETST) enters fiscal 2027 with financial strength, leveraging vertical integration and dual-segment targeting in healthcare, pharmacy, and telemedicine. Read about CEO Giorgio R. Saumat's shareholder letter and the company's growth strategy.
September 9, 2026 — Kairos Pharma CEO to present at H.C. Wainwright conference. Learn about ENV-105 targeting CD105 to overcome cancer drug resistance. KAPA stock update.
September 9, 2026 — Discover the hidden crisis in UTI diagnosis, its impact on women's lives, and how companies like Co-Diagnostics are developing next-gen tools to revolutionize care.
September 9, 2026 — Nutriband CEO Gareth Sheridan to attend Nasdaq LaB Biotech Summit, showcasing AVERSA™ abuse-deterrent technology for fentanyl patches. Learn more about NTRB's innovative transdermal solutions.
September 9, 2026 — Silo Pharma advances PTSD nasal therapy SPC-15 with stability data, participates in IPAC-RS 2026 Nasal Innovation Forum, targeting CNS disorders.
September 9, 2026 — Quantum BioPharma's Lucid-MS gets FDA clearance for Phase 2 trial, a potential breakthrough for MS treatment. Analysts issue buy rating. Learn more about QNTM.
September 9, 2026 — Quantum BioPharma's Lucid-MS gets FDA clearance for Phase 2 MS trial, drawing analyst buy rating. A first-in-class myelin repair approach could transform treatment.